PDL BioPharma enters into non-exclusive license agreement with Eli Lilly

Download PDF Copy

Dec 22 2009

NewsGuard 100/100 Score

PDL BioPharma, Inc. (Nasdaq: PDLI) today announced that it has entered into a non-exclusive license agreement with Eli Lilly and Company (NYSE: LLY) under PDL's Queen et al patents with respect to teplizumab, a humanized anti-CD3 monoclonal antibody, as well as other potential next generation anti-CD3 molecules. Teplizumab is currently being studied by Lilly and its partner MacroGenics for the treatment of individuals with newly-diagnosed type 1 diabetes mellitus. No other details of the licensing agreement were made available.

Lilly currently holds a license to the Queen et al patents with respect to solanezumab, its humanized antibody to beta amyloid which is currently being studied to delay the progression of Alzheimer's disease.

SOURCE PDL BioPharma, Inc.

Posted in:

Tags: Alzheimer's Disease, Antibody, Beta Amyloid, Cancer, CD3, Diabetes, Diabetes Mellitus, Endocrinology, Monoclonal Antibody, Next Generation, Type 1 Diabetes, Type 2 Diabetes, Type I Diabetes

Comments (0)

Download PDF Copy

Suggested Reading

Kyushu University team develops antibody to fight age-related muscle atrophy

Kyushu University team develops antibody to fight age-related muscle atrophy

Novel antibody shows promise for pain relief in peripheral nerves

Novel antibody shows promise for pain relief in peripheral nerves

New trial shows felzartamab reduces proteinuria in IgA nephropathy patients

New trial shows felzartamab reduces proteinuria in IgA nephropathy patients

Phase 3 trial assesses clazakizumab in kidney transplant recipients with caAMR

Phase 3 trial assesses clazakizumab in kidney transplant recipients with caAMR

New antibody platform targets evolving viruses

New antibody platform targets evolving viruses

Antiverse raises £3.5 M ($4.6 M) to advance generative AI antibody design platform

Antiverse raises £3.5 M ($4.6 M) to advance generative AI antibody design platform

Researchers uncover key to combat Campylobacter infections

Researchers uncover key to combat Campylobacter infections

Elevated antibody responses to Epstein-Barr virus linked to increased risk of multiple sclerosis

Elevated antibody responses to Epstein-Barr virus linked to increased risk of multiple sclerosis

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

Post

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...

Researchers develop new antibody with potential to treat several types of cancer